(c) 2024 PillSync.com

lenalidomide 25 mg capsule

1 INDICATIONS AND USAGE Lenalidomide capsules are a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: • Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials ( 1.6 ). 1.1 Multiple Myeloma Lenalidomide capsules in combination with dexamethasone are indicated for the treatment of adult patients with multiple myeloma (MM). Lenalidomide capsules are indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). 1.2 Myelodysplastic Syndromes Lenalidomide capsules are indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma Lenalidomide capsules are indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Follicular Lymphoma Lenalidomide capsules in combination with a rituximab product, are indicated for the treatment of adult patients with previously treated follicular lymphoma (FL). 1.5 Marginal Zone Lymphoma Lenalidomide capsules in combination with a rituximab product, are indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL). 1.6 Limitations of Use Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5) ] .

mylan pharmaceuticals inc.


1 year ago CAPSULE WHITE Mylan LL 25 lenalidomide 25 mg capsule

CAPSULE WHITE Mylan LL 25

16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied

LENALIDOMIDE capsules are available containing 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg or 25 mg of

LENALIDOMIDE. The 2.5 mg capsules are hard-shell gelatin capsules with a green opaque cap and white opaque body filled with white to off-white powder. The capsules are axially printed with MYLAN over LL 2.5 in black ink on both the cap and body. They are available as follows: NDC 0378-1935-28 bottles of 28 capsules NDC 0378-1935-01 bottles of 100 capsules The 5 mg capsules are hard-shell gelatin capsules with a white opaque cap and white opaque body filled with white to off-white powder. The capsules are axially printed with MYLAN over LL 5 in black ink on both the cap and body. They are available as follows: NDC 0378-1936-28 bottles of 28 capsules NDC 0378-1936-01 bottles of 100 capsules The 10 mg capsules are hard-shell gelatin capsules with a green opaque cap and light gray opaque body filled with white to off-white powder. The capsules are axially printed with MYLAN over LL 10 in black ink on both the cap and body. They are available as follows: NDC 0378-1937-28 bottles of 28 capsules NDC 0378-1937-01 bottles of 100 capsules The 15 mg capsules are hard-shell gelatin capsules with a white opaque cap and white opaque body filled with white to off-white powder. The capsules are axially printed with MYLAN over LL 15 in red ink on both the cap and body. They are available as follows: NDC 0378-1941-21 bottles of 21 capsules NDC 0378-1941-01 bottles of 100 capsules The 20 mg capsules are hard-shell gelatin capsules with a green opaque cap and white opaque body filled with white to off-white powder. The capsules are axially printed with MYLAN over LL 20 in red ink on both the cap and body. They are available as follows: NDC 0378-1942-21 bottles of 21 capsules NDC 0378-1942-01 bottles of 100 capsules The 25 mg capsules are hard-shell gelatin capsules with a white opaque cap and white opaque body filled with white to off-white powder. The capsules are axially printed with MYLAN over LL 25 in black ink on both the cap and body. They are available as follows: NDC 0378-1940-21 bottles of 21 capsules NDC 0378-1940-01 bottles of 100 capsules 16.2 Storage Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] 16.3 Handling and Disposal Care should be exercised in the handling of

LENALIDOMIDE capsules.

LENALIDOMIDE capsules should not be opened or broken. If powder from

LENALIDOMIDE capsules contacts the skin, wash the skin immediately and thoroughly with soap and water. If

LENALIDOMIDE contacts the mucous membranes, flush thoroughly with water. Procedures for the proper handling and disposal of anticancer drugs should be considered. Several guidelines on the subject have been published. 1 Dispense no more than a 28-day supply. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.


More pills like CAPSULE Mylan LL 25

Related Pills

lenalidomide 2.5 mg

mylan pharmaceuticals inc.

lenalidomide 15 mg capsule

mylan pharmaceuticals inc.

lenalidomide 10 mg capsule

mylan pharmaceuticals inc.

lenalidomide 5 mg capsule

mylan pharmaceuticals inc.












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site